

=> b reg

FILE 'REGISTRY' ENTERED AT 07:50:52 ON 08 MAR 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 6 MAR 2007 HIGHEST RN 925228-12-2
 DICTIONARY FILE UPDATES: 6 MAR 2007 HIGHEST RN 925228-12-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> d que sta l7

L4 (35972)SEA FILE=REGISTRY ABB=ON PLU=ON >=2 NC5-C6/ES
 L5 STR

Hy---N---Hy---N---Hy
 1 2 3 4 5

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED
 ECOUNT IS UNLIMITED AT 2 4

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 5

STEREO ATTRIBUTES: NONE

L6 (330)SEA FILE=REGISTRY SUB=L4 SSS FUL L5
 L7 47 SEA FILE=REGISTRY ABB=ON PLU=ON L6 AND NCNC3/ES

=> b hcap

FILE 'HCAPLUS' ENTERED AT 07:51:03 ON 08 MAR 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
 held by the publishers listed in the PUBLISHER (PB) field (available
 for records published or updated in Chemical Abstracts after December
 26, 1996), unless otherwise indicated in the original publications.
 The CA Lexicon is the copyrighted intellectual property of the
 the American Chemical Society and is provided to assist you in searching
 databases on STN. Any dissemination, distribution, copying, or storing
 of this information, without the prior written consent of CAS, is
 strictly prohibited.

FILE COVERS 1907 - 8 Mar 2007 VOL 146 ISS 11
 FILE LAST UPDATED: 7 Mar 2007 (20070307/ED)



New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitrn fhitrstr l17 tot

L17 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:754380 HCAPLUS
 DN 137:263071
 TI Preparation of trisubstituted 2,4,6-triamino[1,3,5]triazines as
 anti-telomerase agents
 IN Mailliet, Patrick; Laoui, Abdelazize; Riou,
 Jean-Francois; Doerflinger, Gilles; Mergny, Jean-Louis;
 Hamy, Francois; Caulfield, Thomas
 PA Aventis Pharma S.A., Fr.
 SO PCT Int. Appl., 208 pp.
 CODEN: PIXXD2
 DT Patent
 LA French
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2002076975	A1	20021003	2002WO-FR01005	20020322
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	FR---2822468	A1	20020927	2001FR-0003916	20010323
	CA---2442012	A1	20021003	2002CA-2442012	20020322
	EP---1373252	A1	20040102	2002EP-0720068	20020322
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP2004524349	T	20040812	2002JP-0576233	20020322
	US2003087931	A1	20030508	2002US-0103883	20020325
	US---6887873	B2	20050503		
	US2005070571	A1	20050331	2004US-0993637	20041119
PRAI	2001FR-0003916	A	20010323		
	2001FR-0010370	A	20010802		
	2001US-332009P	P	20011123		
	2002WO-FR01005	W	20020322		
	2002US-0103883	A3	20020325		
OS	MARPAT 137:263071				
GI					




AB Title compds. I [A = XR₁R₂; X = N, O, S, alkyl radical; R₁-2 = H, alkyl, heterocyclyl, etc.; R₃-3' = H, alkyl, isoquinolinyl, quinolinyl, etc.; Ar₁-2 = (un)substituted Ph, etc., and derivs. thereof] were prepared For instance, 2,4-bis[(4-(dimethylamino)-2-methylquinolin-6-yl)amino]-6-chloro[1,3,5]triazine (prior art) was reacted with N,N-dimethyl-1,3-propanediamine in DMF with K₂CO₃ for 15 h at 100° to afford II. Examples include evaluation of all compds. of the invention for telomerase activity. I are anti-cancer agents.

IT 462649-59-8P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[4-[pyrimidin-4-yl]piperazinyl]triazine
 462649-65-6P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[4-[pyrimidin-2-yl]piperazinyl]triazine
 462649-99-6P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[pyrimidin-2-yl]amino]triazine
 462650-15-3P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[4,6-dimethylpyrimidin-2-yl]oxy]triazine
 462650-17-5P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[pyrimidin-2-yl]oxy]triazine
 462650-39-1P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[pyrimidin-2-yl]sulfanyl]triazine
 462650-41-5P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[4,6-dimethylpyrimidin-2-yl]sulfanyl]triazine 462650-96-0P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[pyrimidin-2-yl]amino]triazine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of trisubstituted 2,4,6-triamino[1,3,5]triazines as anti-telomerase agents)
 IT 462649-59-8P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[4-[pyrimidin-4-yl]piperazinyl]triazine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of trisubstituted 2,4,6-triamino[1,3,5]triazines as anti-telomerase agents)

RN 462649-59-8 HCAPLUS
 CN 4,6-Quinolinediamine, N6,N6'-[6-[4-(4-pyrimidinyl)-1-piperazinyl]-1,3,5-triazine-2,4-diyl]bis[2-methyl- (9CI) (CA INDEX NAME)




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
 AN 2001:416931 HCAPLUS
 DN 135:33495
 TI Arylamine derivatives and their use as anti-telomerase agent
 IN Mailliet, Patrick; Riou, Jean-Francois; Mergny, Jean-Louis; Laoui, Abdelazize; Lavelle, Francois; Petitgenet, Odile
 PA Aventis Pharma S.A., Fr.
 SO PCT Int. Appl., 66 pp.
 CODEN: PIXXD2
 DT Patent
 LA French
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2001040218	A1	20010607	2000WO-FR03310	20001127 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR---2801588	A1	20010601	1999FR-0015031	19991129 <--
FR---2801588	B1	20020301		
CA---2392507	A1	20010607	2000CA-2392507	20001127 <--
BR2000015992	A	20020806	2000BR-0015992	20001127 <--
EP---1244650	A1	20021002	2000EP-0985339	20001127 <--
EP---1244650	B1	20030625		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU-200204429	A2	20030428	2002HU-0004429	20001127 <--
JP2003515604	T	20030507	2001JP-0541902	20001127 <--
EE-200200263	A	20030616	2002EE-0000263	20001127 <--
AT---243692	T	20030715	2000AT-0985339	20001127 <--
PT---1244650	T	20031128	2000PT-0985339	20001127 <--
ES---2202206	T3	20040401	2000ES-0985339	20001127 <--
US---6645964	B1	20031111	2000US-0722361	20001128 <--

NO2002002528 A 20020528 2002NO-0002528 20020528 <--
 ZA2002004266 A 20030828 2002ZA-0004266 20020528 <--
 BG----106753 A 20030228 2002BG-0106753 20020529 <--
 US2004053966 A1 20040318 2003US-0658394 20030910 <--
 PRAI 1999FR-0015031 A 19991129 <--
 2000FR-0010561 A 20000811 <--
 2000US-176632P P 20000119 <--
 2000US-218059P P 20000713 <--
 2000WO-FR03310 W 20001127 <--
 2000US-0722361 A3 20001128 <--
 OS MARPAT 135:33495
 AB Nitrogen heterocycles, especially diaminotriazines, were prepared for use as
 telomerase inhibitors and anticancer agents. Thus, 2-amino-4,6-dichloro-
 1,3,5-triazine was treated with 1-methyl-4,6-quinaldinium chloride
 hydrochloride to give 2-amino-4,6-bis(1-methyl-4-amino-6-quinaldinio)amino-
 1,3,5-triazine dichloride hydrochloride which was converted to its free
 base. The free base had a telomerase-inhibiting IC50 of 0.25 µM and a
 cytotoxic IC50 of 0.59-1.9 µM.
 IT 343876-24-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of triazinediamine derivs. as telomerase inhibitors and
 antitumor agents)
 IT 343876-24-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of triazinediamine derivs. as telomerase inhibitors and
 antitumor agents)
 RN 343876-24-4 HCAPLUS
 CN 4,6-Quinolinediamine, N6,N6'-2,4-pyrimidinediylbis[2-methyl-,
 trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'REGISTRY' ENTERED AT 07:08:07 ON 08 MAR 2007)

DEL HIS Y

ACT J394C22/A

L1 (35972)SEA FILE=REGISTRY ABB=ON PLU=ON >=2 NC5-C6/ES

L2 STR

L3 330 SEA FILE=REGISTRY SUB=L1 SSS FUL L2

ACT J394C22A/A

L4 (35972)SEA FILE=REGISTRY ABB=ON PLU=ON >=2 NC5-C6/ES

L5 STR

L6 (330)SEA FILE=REGISTRY SUB=L4 SSS FUL L5
 L7 47 SEA FILE=REGISTRY ABB=ON PLU=ON L6 AND NCNC3/ES

FILE 'HCAPLUS' ENTERED AT 07:10:07 ON 08 MAR 2007

L8 6 L7
 L9 1 (US2004053966 OR US6645964)/PN OR (US2003-658394 OR US2000-7223
 E MAILLIET P/AU
 L10 73 E3-4
 E RIOU J/AU
 L11 235 E3-4,E9-12
 E MERGNY J/AU
 L12 86 E4-5
 E LAQUI A/AU
 L13 30 E3-5
 E LAVELLE F/AU
 L14 88 E3,E8
 E PETITGENET O/AU
 L15 5 E3-4
 L16 1 (FR2000-10561 OR FR99-15031)/AP,PRN
 L17 2 L8 AND L9-16
 L18 4 L8 NOT L17

FILE 'MEDLINE' ENTERED AT 07:42:12 ON 08 MAR 2007

L19 0 L7

FILE 'EMBASE' ENTERED AT 07:42:23 ON 08 MAR 2007

L20 0 L7

FILE 'BIOSIS' ENTERED AT 07:42:30 ON 08 MAR 2007

L21 0 L7

FILE 'USPATFULL, USPAT2' ENTERED AT 07:42:36 ON 08 MAR 2007

L22 10 L7
 L23 2 L22 AND L9,L16
 L24 8 L22 NOT L23
 L25 0 L24 AND (PY<=2000 OR AY<=2000 OR PRY<=2000)

FILE 'TOXCENTER' ENTERED AT 07:45:39 ON 08 MAR 2007

L26 5 L7

=>